

## The First Macrocyclic Glycoterpenoid Having Glucosamine and Isosteviol Moieties

Bulat F. Garifullin,<sup>a</sup> Irina Yu. Strobykina,<sup>a</sup> Radmila R. Sharipova,<sup>a</sup>  
Marionella A. Kravchenko,<sup>b</sup> and Vladimir E. Kataev<sup>a@</sup>

<sup>a</sup>Arbuzov Institute of Organic and Physical Chemistry, Kazan Scientific Center, Russian Academy of Sciences, 420088 Kazan, Russia

<sup>b</sup>Ural Research Institute for Phthysiology, Ministry of Health Protection of the Russian Federation, 620039 Ekaterinburg, Russia

@Corresponding author E-mail: kataev@iopc.ru

*The first macrocyclic glycoterpenoid possessing two glucosamine residues and two moieties of diterpenoid isosteviol has been synthesized. It inhibited the in vitro growth of the H37Rv strain of M. Tuberculosis at the MIC value of 12.5 µg/mL.*

**Keywords:** Terpenoids, isosteviol, glucosamine, glycosides, macrocycles, macrocyclic glycoterpenoids, antitubercular activity, *Micobacterium Tuberculosis*.

## Первый макроциклический гликотерпеноид, содержащий остатки глюкозамина и изостевиола

Б. Ф. Гарифуллин,<sup>a</sup> И. Ю. Стробыкина,<sup>a</sup> Р. Р. Шарипова,<sup>a</sup> М. А. Кравченко,<sup>b</sup>  
В. Е. Катаев<sup>a@</sup>

<sup>a</sup>Институт органической и физической химии им. А.Е. Арбузова КазНЦ РАН, 420088 Казань, Россия

<sup>b</sup>Уральский НИИ фтизиопульмонологии Минздрава РФ, 620039 Екатеринбург, Россия

@E-mail: kataev@iopc.ru

*Синтезирован первый макроциклический гликотерпеноид с двумя остатками глюкозамина и двумя остатками diterпеноида изостевиола. Он ингибирует in vitro рост штамма H37Rv Micobacterium Tuberculosis при значении МИК 12.5 мкг/мл.*

**Ключевые слова:** Терпеноиды, изостевиол, глюкозамин, гликозиды, макроциклы, макроциклические гликотерпеноиды, антитуберкулезная активность, *Micobacterium Tuberculosis*.

Recently we have reported the synthesis of macrocyclic glycoterpenoids having moieties of diterpenoid isosteviol and residues of glucuronic acid or trehalose.<sup>[1-4]</sup> It was found that these macrocycles inhibited the *in vitro* growth of H37Rv strain of *M. Tuberculosis* at the minimal inhibition concentration (MIC) value of 12.5 mg/mL that is comparable to the activity of antitubercular drug pyrazinamide.<sup>[3,4]</sup> Herein, the synthesis of the first macrocyclic glycoterpenoid having isosteviol and glucosamine residues is reported. We followed the previously proposed approach<sup>[1]</sup> according


to which the terminal reactive groups of binuclear isosteviol derivative are functionalized with carbohydrate residues, and these ones then are coupled by any linker.

The diol **1**<sup>[4]</sup> was used as a starting compound in which two isosteviol molecules were bonded to each other with an octamethylene linker attached to their C(16) atoms, while carboxyl groups of these isosteviol moieties were functionalized by 6-hydroxyhexyl chains. The reaction of diol **1** with glucosamine bromo derivative **2** afforded diglycoside **3** in which amine groups were protected

by trichloroethyl carbonate (Troc) groups.<sup>[5]</sup> For the macrocyclization of diglycoside **3** its protecting groups were removed by the reaction with activated powdered zinc in glacial acetic acid, and diglycoside **4** were obtained in 87 % yield.<sup>†</sup> The MALDI spectrum of this compound demonstrated peaks at  $m/z$  1582.1,  $[(M+H)^+]$ , (calc.  $m/z$  1582.0,  $[(M+H)^+]$ ,  $C_{86}H_{137}N_2O_{24}$ ),  $m/z$  1604.1,  $[(M+Na)^+]$ , (calc.  $m/z$  1603.9,  $[(M+Na)^+]$ ,  $C_{86}H_{136}N_2NaO_{24}$ ), and  $m/z$  1620.1,  $[(M+K)^+]$ , (calc.  $m/z$  1619.9,  $[(M+K)^+]$ ,  $C_{86}H_{136}KN_2O_{24}$ ). In the  $^1H$  NMR spectrum of diglycoside **4** the signals of the protons of Troc protecting group disappeared, and the signals of the protons at C<sup>2</sup> atoms of glucosamine residues were shifted upfield in keeping with the literature data,<sup>[6,7]</sup> and resonated as a doublet of doublets at 2.93 ppm with vicinal coupling constants of 10.2 and 3.3 Hz. The anomeric protons of diglycoside **4** resonated at 4.85 ppm as a doublet with a vicinal coupling constant of 3.2 Hz indicating  $\alpha$ -orientation of the glycoside

bonds. The reaction of diglycoside **4** with sebacoyl dichloride provided macrocyclic glycoterpenoid **5**<sup>‡</sup> in 23 % yield (after column chromatography). The MALDI spectrum of macrocycle **5** showed peaks at  $m/z$  1748.1,  $[(M+H)^+]$ , (calc.  $m/z$  1748.1,  $[(M+H)^+]$ ,  $C_{96}H_{151}N_2O_{26}$ ),  $m/z$  1770.1,  $[(M+Na)^+]$ , (calc.  $m/z$  1770.0,  $[(M+Na)^+]$ ,  $C_{96}H_{150}N_2NaO_{26}$ ), and  $m/z$  1786.1,  $[(M+K)^+]$ , (calc.  $m/z$  1786.0,  $[(M+K)^+]$ ,  $C_{96}H_{150}KN_2O_{26}$ ). In the  $^1H$  NMR spectrum of macrocycle **5** the signals of protons of the diamide linker appeared, and the signals of the protons at C<sup>2</sup> atoms of glucosamine residues were shifted downfield and resonated as a multiplet at 4.32–4.37 ppm. The anomeric protons of macrocyclic glycoterpenoid **5** appeared at 4.83 ppm as a doublet with a vicinal coupling constant of 3.6 Hz that testified to the  $\alpha$ -orientation of the glycoside bonds.

The *in vitro* inhibitory activity of macrocyclic glycoterpenoid **5** toward the H37Rv strain of *M. Tuberculosis*



**Scheme 1.** Reagents and conditions: (i) ZnCl<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, yield 20 %; (ii) Zn, AcOH, yield 87 %; (iii) ClOC(CH<sub>2</sub>)<sub>8</sub>COCl, CH<sub>2</sub>Cl<sub>2</sub>, Py, yield 23 %.

was assayed.<sup>§</sup> It was found that this compound inhibited the in vitro growth of this strain of pathogen at MIC 12.5 µg/mL, that is, at the level comparable to the known antitubercular drug pyrazineamide.<sup>[8]</sup> Comparing the obtained MIC value with those founded earlier for macrocyclic glycoterpenoids having residues of glucuronic acid<sup>[3]</sup> and trehalose<sup>[4]</sup> one can reveal that both the size of macrocycle and the nature of the carbohydrate residues do not influence on antitubercular activity of the macrocyclic glycoterpenoids under consideration.

In conclusion, the macrocyclic glycoterpenoid having two isosteviol moieties and two glucosamine residues bonded by polymethylene linkers with ester and amide groups has been synthesized for the first time. It inhibited the in vitro growth of the H37Rv strain of *M. Tuberculosis* at the MIC value of 12.5 µg/mL.

**Acknowledgments.** The microbiological assay was performed under financial support of the Russian Science Foundation (grant № 14-50-00014).

## Notes and References

<sup>†</sup>*Diglycoside (4)*. To a solution of diglycoside **3** (0.18 g, 0.09 mmol) in AcOH (4 mL) powdered Zn (0.6 g) was added under argon. The reaction mixture was stirred for 3 h at room temperature, then it was concentrated under reduced pressure. The residue was diluted with CH<sub>2</sub>Cl<sub>2</sub>, washed with 5 % NaHCO<sub>3</sub> and water and brine, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. Diglycoside **4** was obtained as white foam in 87 % yield (0.13 g). Found, %: C 65.05, H 8.49, N 1.68. C<sub>86</sub>H<sub>136</sub>N<sub>2</sub>O<sub>24</sub>. Calculated, %: C 65.29, H 8.66, N 1.77. Mass spectrum (MALDI TOF) *m/z* (%): 1582.1 (100), [(M+H)<sup>+</sup>], 1604.1 (100), [(M+Na)<sup>+</sup>], and 1620.1 (100), [(M+K)<sup>+</sup>]. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 30 °C) δ ppm: 0.70 (s, 6H, C<sup>20</sup>H<sub>3</sub>, C<sup>20</sup>H<sub>3</sub>), 0.90 (s, 6H, C<sup>17</sup>H<sub>3</sub>, C<sup>17</sup>H<sub>3</sub>), 1.16 (s, 6H, C<sup>18</sup>H<sub>3</sub>, C<sup>18</sup>H<sub>3</sub>), 0.81–1.89 [m, 66 H, *ent*-beyeran skeleton, 2 linkers (CH<sub>2</sub>)<sub>4</sub> and linker (CH<sub>2</sub>)<sub>6</sub>], 2.02 (s, 6H, CH<sub>3</sub>CO, C<sup>1</sup>H<sub>3</sub>CO), 2.07 (s, 6H, CH<sub>3</sub>CO, C<sup>1</sup>H<sub>3</sub>CO), 2.08 (s, 6H, CH<sub>3</sub>CO, C<sup>1</sup>H<sub>3</sub>CO), 2.15 (d, 2H, *J* = 13.5 Hz, C<sup>3</sup>H<sub>eq</sub>, C<sup>3</sup>H<sub>eq</sub>), 2.30 (t, 4H, *J* = 7.4 Hz, C<sup>16</sup>OC(O)CH<sub>2</sub>, C<sup>16</sup>OC(O)CH<sub>2</sub>), 2.93 (dd, 2H, *J* = 10.2, 3.3 Hz, H<sup>2s</sup>, H<sup>2s</sup>), 3.40–3.49 (m, 2H, C<sup>19</sup>OC(O)(CH<sub>2</sub>)<sub>5</sub>CH<sub>A</sub>, C<sup>19</sup>OC(O)(CH<sub>2</sub>)<sub>5</sub>CH<sub>A</sub>), 3.66–3.75 (m, 2H, C<sup>19</sup>OC(O)(CH<sub>2</sub>)<sub>5</sub>CH<sub>B</sub>, C<sup>19</sup>OC(O)(CH<sub>2</sub>)<sub>5</sub>CH<sub>B</sub>), 3.89–4.11 (m, 8H, H<sup>6s</sup>, H<sup>6s</sup>, C<sup>19</sup>(O)OCH<sub>2</sub>, C<sup>19</sup>OC(O)CH<sub>2</sub>, H<sup>5s</sup>, H<sup>5s</sup>), 4.28 (dd, 2H, *J* = 12.3, 4.7 Hz, H<sup>6s</sup>, H<sup>6s</sup>), 4.72 (dd, 2H, *J* = 10.5, 4.2 Hz, C<sup>16</sup>H, C<sup>16</sup>H), 4.85 (d, 2H, *J* = 3.2 Hz, H<sup>1s</sup>, H<sup>1s</sup>), 4.95 (t, 2H, *J* = 9.8 Hz, H<sup>4s</sup>, H<sup>4s</sup>), 5.12 (t, 2H, *J* = 9.7 Hz, H<sup>3s</sup>, H<sup>3s</sup>).

<sup>‡</sup>*Macrocyclic glycoterpenoid (5)*. A solution of 0.012 g (0.05 mmol) of sebacoyl dichloride in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) was added to a solution of 0.08 g (0.05 mmol) diglycoside **4** and pyridine 0.008 g (0.1 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) under argon. The reaction mixture was stirred for 8 h at room temperature, then diluted with CH<sub>2</sub>Cl<sub>2</sub>, washed with 0.1 N HCl and water, dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent – hexane-ethyl acetate from 5:1 to 1:1 mixture). Compound **5** was obtained as a white foam in 23 % yield (0.02 g), [α]<sub>D</sub><sup>20</sup> +13.8° (*c* 0.53; CH<sub>2</sub>Cl<sub>2</sub>). Found, %: C 66.01, H 8.60, N 1.66. C<sub>96</sub>H<sub>150</sub>N<sub>2</sub>O<sub>26</sub>. Calculated, %: C 65.95, H 8.65, N 1.60. Mass spectrum (MALDI TOF) *m/z* (%): 1748.1 (100), [(M+H)<sup>+</sup>], 1770.1 (93), [(M+Na)<sup>+</sup>], 1786.1 (83), [(M+K)<sup>+</sup>]. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>, 30 °C) δ ppm: 0.70 (s, 6H, C<sup>20</sup>H<sub>3</sub>, C<sup>20</sup>H<sub>3</sub>),

0.91 (s, 6H, C<sup>17</sup>H<sub>3</sub>, C<sup>17</sup>H<sub>3</sub>), 1.16 (s, 6H, C<sup>18</sup>H<sub>3</sub>, C<sup>18</sup>H<sub>3</sub>), 0.80–1.89 [m, 78H, *ent*-beyeran skeleton, 2 linkers (CH<sub>2</sub>)<sub>4</sub> and 2 linkers (CH<sub>2</sub>)<sub>6</sub>], 2.00 (s, 6H, CH<sub>3</sub>CO, C<sup>1</sup>H<sub>3</sub>CO), 2.03 (s, 6H, CH<sub>3</sub>CO, C<sup>1</sup>H<sub>3</sub>CO), 2.09 (s, 6H, CH<sub>3</sub>CO, C<sup>1</sup>H<sub>3</sub>CO), 2.10–2.19 (m, 6H, C<sup>3</sup>H<sub>eq</sub>, C<sup>3</sup>H<sub>eq</sub>, 2 NHC(O)CH<sub>2</sub>), 2.29–2.33 (m, 4H, C<sup>16</sup>OC(O)CH<sub>2</sub>, C<sup>16</sup>OC(O)CH<sub>2</sub>), 3.39–3.47 (m, 2H, C<sup>19</sup>(O)O(CH<sub>2</sub>)<sub>5</sub>CH<sub>A</sub>, C<sup>19</sup>OC(O)(CH<sub>2</sub>)<sub>5</sub>CH<sub>A</sub>), 3.65–3.71 (m, 2H, C<sup>19</sup>OC(O)(CH<sub>2</sub>)<sub>5</sub>CH<sub>B</sub>, C<sup>19</sup>(O)O(CH<sub>2</sub>)<sub>5</sub>CH<sub>B</sub>), 3.91–4.12 (m, 8H, C<sup>19</sup>(O)OCH<sub>2</sub>, C<sup>19</sup>(O)OCH<sub>2</sub>, H<sup>6s</sup>, H<sup>6s</sup>, H<sup>5s</sup>, H<sup>5s</sup>), 4.24 (dd, 2H, *J* = 12.4, 4.5 Hz, H<sup>6s</sup>, H<sup>6s</sup>), 4.32–4.38 (m, 2H, H<sup>2s</sup>, H<sup>2s</sup>), 4.68 (dd, 2H, *J* = 10.2, 4.4 Hz, C<sup>16</sup>H, C<sup>16</sup>H), 4.83 (d, 2H, *J* = 3.6 Hz, H<sup>1s</sup>, H<sup>1s</sup>), 5.11 (t, 2H, *J* = 9.9 Hz, H<sup>4s</sup>, H<sup>4s</sup>), 5.21 (t, 2H, *J* = 10.0 Hz, H<sup>3s</sup>, H<sup>3s</sup>), 5.82 (d, 2H, *J* = 9.3 Hz, 2NH).

NMR experiments were carried out with Avance-400 and Avance-500 (Bruker) spectrometers. MALDI mass spectra were obtained with a time-of-flight mass spectrometer Ultraflex III TOF/TOF (Bruker Daltonik GmbH, Bremen, Germany) equipped with a Nd:YAG laser and a collision cell. The spectra of positive ions were recorded in a reflectron mode and were processed using the software FlexAnalysis 3.0 (Bruker Daltonik GmbH, Bremen, Germany). Samples were prepared as 0.1 % solutions of compounds in CHCl<sub>3</sub>. The matrix was *p*-nitroaniline (Acros). The completeness of the reactions and the purity of the compounds were monitored by TLC on Sorbfil plates (Sorbfil, Russia). Spots were detected by treatment with the 5 % solution of sulfuric acid, followed by heating up to 120 °C. Diglycoside **3** was synthesized according to the published procedure.<sup>[5]</sup>

<sup>§</sup>Macrocyclic glycoterpenoid **5** was tested for antitubercular activity by the vertical diffusion method on a *Novaya* solid nutrient medium using H37Rv laboratory strain as a test culture. The nutrient medium was placed in 5 mL test tubes and inoculated with 0.1 mL of test culture diluted to a turbidity of 10 units (according to the standard developed by the Tarasevich State Scientific Research Institute for Standardization and Quality Control of Biologicals), and the test tubes were incubated for 24 h to grow tuberculosis bacteria. The test tubes were then set vertically, and 0.3 mL of a solution of **5** in aqueous alcohol with a concentration of 12.5, 6.2, 3.1, 1.5, 0.7, 0.35, or 0.1 µg/mL was added dropwise (test solutions were prepared by serial decimal dilutions of the initial solution of 100 µg of macrocycle **5** in the mixture of 5 mL of 96 % ethanol and 5 mL of sterile distilled water). The test tubes were incubated for 10 days at 37 °C under sterile conditions, and the zone of bacterial growth inhibition was measured. An inhibition zone of longer than 10 mm indicated tuberculostatic activity. Antitubercular drugs isoniazid which was used as a control inhibited *M. tuberculosis* growth at MIC 0.1 µg/mL.

1. Andreeva O.V., Sharipova R.R., Garifullin B.F., Strobykina I.Yu., Kataev V.E. *Chem. Nat. Compd.* **2015**, *51*, 689–692.
2. Garifullin B.F., Sharipova R.R., Strobykina I.Yu., Andreeva O.V., Kataev V.E. *Chem. Nat. Compd.* **2015**, *51*, 886–889.
3. Andreeva O.V., Sharipova R.R., Strobykina I.Yu., Kravchenko M.A., Strobykina A.S., Voloshina A.D., Musin R.Z., Kataev V.E. *Russ. J. Org. Chem.* **2015**, *51*, 1324–1333.
4. Garifullin B.F., Sharipova R.R., Andreeva O.V., Strobykina I.Yu., Kravchenko M.A., Kataev V.E. *Russ. J. Org. Chem.*, **2015**, *51*, 1488–1498.
5. Garifullin B.F., Strobykina I.Yu., Sharipova R.R., Bazanova O.B., Kataev V.E. *Macrocyclics* **2016**, *9*, 54–58.
6. Miyajima K., Achiwa K. *Chem. Pharm. Bull.* **1997**, *45*, 312–320.
7. De Nisco M., Pedatella S., Bektaş S., Nucci A., Caputo R. *Carbohydrate Res.* **2012**, *356*, 273–277.
8. Donald P.R. *Tuberculosis* **2010**, *90*, 279–292.

Received 01.03.2016

Accepted 07.04.2016